143 related articles for article (PubMed ID: 21818391)
1. Respiratory paradoxical adverse drug reactions associated with acetylcysteine and carbocysteine systemic use in paediatric patients: a national survey.
Mallet P; Mourdi N; Dubus JC; Bavoux F; Boyer-Gervoise MJ; Jean-Pastor MJ; Chalumeau M
PLoS One; 2011; 6(7):e22792. PubMed ID: 21818391
[TBL] [Abstract][Full Text] [Related]
2. Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho-pulmonary disease.
Chalumeau M; Duijvestijn YC
Cochrane Database Syst Rev; 2013 May; (5):CD003124. PubMed ID: 23728642
[TBL] [Abstract][Full Text] [Related]
3. Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho-pulmonary disease.
Duijvestijn YC; Mourdi N; Smucny J; Pons G; Chalumeau M
Cochrane Database Syst Rev; 2009 Jan; (1):CD003124. PubMed ID: 19160217
[TBL] [Abstract][Full Text] [Related]
4. [Mucolytic agents for acute respiratory tract infections in infants: a pharmacoepidemiologic problem?].
Chalumeau M; Chéron G; Assathiany R; Moulin F; Bavoux F; Bréart G; Pons G
Arch Pediatr; 2002 Nov; 9(11):1128-36. PubMed ID: 12503503
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
Rogliani P; Matera MG; Page C; Puxeddu E; Cazzola M; Calzetta L
Respir Res; 2019 May; 20(1):104. PubMed ID: 31133026
[TBL] [Abstract][Full Text] [Related]
6. Use of mucolytics in COPD: A Delphi consensus study.
Papi A; Avdeev S; Calverley PMA; Cordeiro CR; Jesenak M; Koblížek V; Petkova D; Rogliani P; Tarraf H; Tzanakis N; Ulmeanu R; Uzaslan E; Adir Y
Respir Med; 2020 Dec; 175():106190. PubMed ID: 33217537
[TBL] [Abstract][Full Text] [Related]
7. Paradoxical adverse drug reactions: descriptive analysis of French reports.
Hakimi Y; Petitpain N; Pinzani V; Montastruc JL; Bagheri H
Eur J Clin Pharmacol; 2020 Aug; 76(8):1169-1174. PubMed ID: 32418024
[TBL] [Abstract][Full Text] [Related]
8. [Mucolytic drugs: towards a contraindication in infants].
Mourdi N; Dubus JC; Bavoux F; Boyer-Gervoise M; Jean-Pastor MJ; Chalumeau M
Arch Pediatr; 2010 Jun; 17(6):735-6. PubMed ID: 20654866
[No Abstract] [Full Text] [Related]
9. Theory and practice of the use of expectorants reviewed from clinical aspects.
Nagy G
Ther Hung; 1984; 32(1):6-12. PubMed ID: 6400475
[No Abstract] [Full Text] [Related]
10. Perceived adverse drug reactions among non-institutionalized children and adolescents in Germany.
Knopf H; Du Y
Br J Clin Pharmacol; 2010 Sep; 70(3):409-17. PubMed ID: 20716242
[TBL] [Abstract][Full Text] [Related]
11. First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals.
Durrieu G; Palmaro A; Pourcel L; Caillet C; Faucher A; Jacquet A; Ouaret S; Perault-Pochat MC; Kreft-Jais C; Castot A; Lapeyre-Mestre M; Montastruc JL;
Drug Saf; 2012 Oct; 35(10):845-54. PubMed ID: 22967189
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
[TBL] [Abstract][Full Text] [Related]
13. A controlled multicenter pediatric study in the treatment of acute respiratory tract diseases with the aid of a new specific compound, erdosteine (IPSE, Italian Pediatric Study Erdosteine).
Titti G; Lizzio A; Termini C; Negri P; Fazzio S; Mancini C
Int J Clin Pharmacol Ther; 2000 Aug; 38(8):402-7. PubMed ID: 10984014
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Reporting Adverse Drug Reactions in Paediatric Patients in a University Hospital in the Netherlands.
Dittrich ATM; Draaisma JMT; van Puijenbroek EP; Loo DMWMT
Paediatr Drugs; 2020 Aug; 22(4):425-432. PubMed ID: 32557243
[TBL] [Abstract][Full Text] [Related]
15. [Mucolytic therapy for respiratory system diseases. Clinical-experimental results before and after treatment with Transbronchin].
Primer G
Ther Ggw; 1975 Aug; 114(8):1251-66. PubMed ID: 1108276
[No Abstract] [Full Text] [Related]
16. Model systems for the evaluation of mucolytic drugs: acetylcysteine and S-carboxymethylcysteine.
Livingstone CR; Andrews MA; Jenkins SM; Marriott C
J Pharm Pharmacol; 1990 Feb; 42(2):73-8. PubMed ID: 1972405
[TBL] [Abstract][Full Text] [Related]
17. Carbocisteine: frequent cutaneous adverse effects.
Prescrire Int; 2007 Feb; 16(87):17. PubMed ID: 17326276
[TBL] [Abstract][Full Text] [Related]
18. Adverse drug reactions in the paediatric population in Denmark: a retrospective analysis of reports made to the Danish Medicines Agency from 1998 to 2007.
Aagaard L; Weber CB; Hansen EH
Drug Saf; 2010 Apr; 33(4):327-39. PubMed ID: 20297864
[TBL] [Abstract][Full Text] [Related]
19. Preventive nebulization of mucolytic agents and bronchodilating drugs in invasively ventilated intensive care unit patients (NEBULAE): study protocol for a randomized controlled trial.
van der Hoeven SM; Binnekade JM; de Borgie CA; Bosch FH; Endeman H; Horn J; Juffermans NP; van der Meer NJ; Merkus MP; Moeniralam HS; van Silfhout B; Slabbekoorn M; Stilma W; Wijnhoven JW; Schultz MJ; Paulus F
Trials; 2015 Sep; 16():389. PubMed ID: 26329352
[TBL] [Abstract][Full Text] [Related]
20. Adverse drug reactions in Nigerian children: a retrospective review of reports submitted to the Nigerian Pharmacovigilance Centre from 2005 to 2012.
Obebi Cliff-Eribo K; Sammons H; Star K; Ralph Edwards I; Osakwe A; Choonara I
Paediatr Int Child Health; 2016 Nov; 36(4):300-304. PubMed ID: 26384567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
